Antibodies of the IgG4—but not the IgG1 ... This was demonstrated for IgG1, but is likely to also apply for IgG2, IgG3, IgE and IgM. The evolutionary advantage of functional monovalency ...
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage anti-immunoglobulin E (IgE) monoclonal antibody, RPT904, designed to treat various ...
Serum levels of polyclonal IgG, IgA and IgM are usually decreased in patients with multiple myeloma (MM); however, little is known about the prognostic significance of polyclonal levels of IgE in ...
RPT904 is being developed to offer patients a potentially improved therapeutic option compared to omalizumab (marketed as Xolair ®), an anti-IgE monoclonal antibody approved for several allergic ...